Protocol Name: ASSESS: Double-blind, placebo-controlled, Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome
Protocol #: 22419
Indication: Alport Syndrome
GFR: ≥45
Principal Investigator: Ankit Mehta, MD
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246